申请人:TOYO SUISAN KAISHA, LTD.
公开号:US20020052327A1
公开(公告)日:2002-05-02
A method for immunosuppression in a subject comprising administering to the subject in need thereof, a pharmaceutically effective amount of at least one sulfoquinovosylacylglycerol derivative represented by General formula (1-1):
1
wherein R
101
represents an acyl residue of a higher fatty acid, and R
102
represents a hydrogen atom or an acyl residue of a higher fatty acid; and a pharmaceutically acceptable salt thereof. Of the sulfoquinovosylacylglycerol derivatives, &bgr;-sulfoquinovosylacylglycerols are novel compounds. The present invention also relates to pharmaceutical composition comprising a pharmaceutically effective amount of the &bgr;-sulfoquinovosylacylglycerols and/or its pharmaceutically acceptable salt; and a pharmaceutically acceptable excipient. The pharmaceutical composition may be used as an immunosuppressive agent, anticancer agent and DNA polymerase &agr; inhibitor.
一种在需要免疫抑制的主体中进行的免疫抑制方法,包括向该主体给药至少一种由通用公式(1-1)表示的磺酰基糖醇基甘油酯衍生物的药物有效量:
1
其中R
101
代表一种较高脂肪酸的酰基残基,R
102
代表一个氢原子或一个较高脂肪酸的酰基残基;以及一种药物可接受的盐。在磺酰基糖醇基甘油酯衍生物中,β-磺酰基糖醇基甘油酯是新颖的化合物。本发明还涉及包含β-磺酰基糖醇基甘油酯和/或其药物可接受的盐的药物有效量的药物组合物;以及一种药物可接受的辅料。该药物组合物可作为免疫抑制剂、抗癌剂和DNA聚合酶α抑制剂使用。